| "An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP). " |
Completed |
Asfotase Alfa |
2 |
ENB-010-10 |
KFSH & RC-R |
| An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors. |
Completed |
Everolimus |
3b |
CRAD001K24133 |
KFSH & RC-R |
| An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I) |
Ongoing |
ABT-450/r/ABT-267+ABT-333 (-/+) Ribavirin (RBV) |
3b |
M14-423 |
KKUH |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) |
Ongoing |
A4250 |
3 |
A4250-008 |
KFSH&RC-R |
| "An open-label extension study of the long-term safety, tolerability and efficacy of Ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension(CTEPH)." |
Completed |
Ambrisentan |
3 |
116457 |
KFMC |
| AN OPEN LABEL, SINGLE ARM, MULTICENTER,SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT |
Completed |
Atezolizumab (MPDL3280A; RO5541267) |
3 |
MO29983 |
KFSH & RC-R |
| An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency |
Completed |
Sebelipase alfa (SBC-102) |
2 |
LAL-CL03 |
KFSH & RC-R |
| "An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure " |
Completed |
Dapagliflozin |
3 |
D169CC00001 |
KKUH |
| An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Ongoing |
Hydroxychloroquine sulphate |
3 |
version 8 |
QCH |
| "ALL SCTped 2012 FORUM Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia" |
Ongoing |
BUSULFAN |
3 |
CT17/016/R |
NGHA-R |
